Does DICE Therapeutics Inc. (DICE) Have Insiders Buying Shares?


As of Wednesday close, DICE Therapeutics Inc.’s (NASDAQ:DICE) stock was up $0.07, moving up 0.19 percent to $33.47. The average number of shares traded per day over the past five days has been 294,120 shares. 4 times new highs have been achieved over the past 5 days, with a $1.40 gain in that time frame. In the last twenty days, the average volume was 455,595, while in the previous 50 days, it was 1,023,134.

Since last month, DICE stock retreated -3.85%. Shares of the company fell to $30.26 on 11/17/22, the lowest level in the past month. A 52-week high of $45.99 was reached on 10/11/22 after having rallying from a 52-week low of $12.64. Since the beginning of this year, DICE’s stock price has risen by 32.24% or $8.16, and marked a new high 2 times. However, the stock has declined by -27.22% since its 52-week high.

Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report


DICE stock investors should be aware that DICE Therapeutics Inc. (DICE) stock had its last reported insider trading activity 38 days ago on Oct 17. RA CAPITAL MANAGEMENT, L.P., the Director of the company, purchased of 1,640,000 shares for $36.50 on Oct 17. It resulted in a $59,860,000 investment by the insider.

Financial Health

In the three months ended June 29, DICE Therapeutics Inc.’s quick ratio stood at 23.00, while its current ratio was 23.00, showing that the company is able to pay off its debt. Based on annual data, DICE earned $48.73 million in gross profit and brought in $1.12 million in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -15.10%. Return on equity (ROE) for the past 12 months was -26.80%.

According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. While analysts expected DICE Therapeutics Inc. to report -$0.55 quarterly earnings, the actual figure was -$0.58 per share, beating the consensus estimate by -5.50%. During the quarter, the company generated -$20.49 million in EBITDA. The liabilities of DICE Therapeutics Inc. were 23.88 million at the end of its most recent quarter ended June 29, and its total debt was $13.9 million. The value of shareholders’ equity is $47.67 million.

Technical Picture

This quick technical analysis looks at DICE Therapeutics Inc.’s (DICE) price momentum. With a historical volatility rate of 29.75%, the RSI 9-day stood at 53.42% on 23 November.

With respect to its five-day moving average, the current DICE Therapeutics Inc. price is up by +4.37% percent or $1.40. At present, DICE shares trade +0.60% above its 20-day simple moving average and +92.03% percent above its 100-day simple moving average. However, the stock is currently trading approximately +70.68% above its SMA50 and +95.50% above its SMA200.

Stochastic coefficient K was 50.85% and Stochastic coefficient D was 42.98%, while ATR was 2.36. Given the Stochastic reading of 56.51% for the 14-day period, the RSI (14) reading has been calculated as 54.34%. As of today, the MACD Oscillator reading stands at 0.21, while the 14-day reading stands at 0.52.

Analyst Ratings

Guggenheim launched its rating on DICE Therapeutics Inc. (NASDAQ: DICE) to a Buy in a note to investors on November 15, 2022. DICE Therapeutics Inc. (DICE) has been rated Buy by analysts. According to 0 brokerage firms, DICE is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate DICE Therapeutics Inc. stock as buy, with 7 recommending it as overweight.

With a median target price of $61.00, the current consensus forecast for the stock is $54.00 – $77.00. Based on these forecasts, analysts predict DICE Therapeutics Inc. (DICE) will achieve an average price target of $64.43.


Please enter your comment!
Please enter your name here